Metastatic Melanoma Therapeutics Market, by Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, and Surgery), by Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), by End User (Hospitals, Specialty Clinics, Home Healthcar

Metastatic Melanoma Therapeutics Market, by Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, and Surgery), by Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), by End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Melanoma is a severe form of cancer, commonly known as skin cancer. The population residing at higher altitude levels or in the close proximity to the equator, are the most susceptible to melanoma, as the symptoms are prominently initiated post-exposure to Ultraviolet (UV) radiation that results in blistering sunburns. If diagnosed early in stage 0, melanoma can be surgically cured to almost 100%; however, when the disease metastizes in a body, it becomes strenuous to treat it due to the availability of a restricted range of treatment options. The selection of treatment line or systemic drug therapy entirely depends on the stage of melanoma.
Metastatic melanoma is the most severe stage (IV) of skin cancer that occurs when melanoma penetrates the skin deeper to reach various parts of a body, predominantly the subcutaneous tissue layer under the skin, lungs, bones, liver, brain, and lymph nodes. In the most severe case of metastasis, the gastrointestinal tract, adrenal glands, spleen, and heart can also be affected. Currently, only a limited set of therapies are available to promisingly treat burgeoning cases of metastatic melanoma patients. The disease thus requires more efficient and effective treatment options.
Market Dynamics
High incidence of melanoma leading to large patient pool is one major factor driving the global metastatic melanoma therapeutics market growth. Melanoma of the skin is the 19th most prevalent cancer in both men and women, according to the World Cancer Research Fund. Globally, the number of cases reported were nearly 300,000 new cases in 2018, which will boost the growth of global metastatic melanoma therapeutics market.
Key features of the study:
This report provides in-depth analysis of the global metastatic melanoma therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the metastatic melanoma therapeutics market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
Key companies covered as a part of this study include Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Genentech Inc., F. Hoffmann-La Roche AG., Amgen Inc., AstraZeneca, Daiichi Sankyo Company, Limited., AB Sciences., AgonOX, Inc., Eisai Co., Ltd, GlaxoSmithKline, plc., Pfizer, Inc., and Vical, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global metastatic melanoma therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the metastatic melanoma therapeutics market
Detailed Segmentation:
Global Metastatic melanoma therapeutics Market, By Therapy:
Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Surgery
Global Metastatic melanoma therapeutics Market, By Stages:
Stage 0
Stage I
Stage II
Stage III
Stage IV
Global Metastatic melanoma therapeutics Market, By End User:
Hospitals
Specialty Clinics
Home Healthcare
Others
Global Metastatic melanoma therapeutics Market, By Region:
North America
By Therapy
Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Surgery
By Stages
Stage 0
Stage I
Stage II
Stage III
Stage IV
By End User
Hospitals
Specialty Clinics
Home Healthcare
Others
By Country
U.S.
Canada
Latin America
By Therapy
Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Surgery
By Stages
Stage 0
Stage I
Stage II
Stage III
Stage IV
By End User
Hospitals
Specialty Clinics
Home Healthcare
Others
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Therapy
Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Surgery
By Stages
Stage 0
Stage I
Stage II
Stage III
Stage IV
By End User
Hospitals
Specialty Clinics
Home Healthcare
Others
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Therapy
Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Surgery
By Stages
Stage 0
Stage I
Stage II
Stage III
Stage IV
By End User
Hospitals
Specialty Clinics
Home Healthcare
Others
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Therapy
Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Surgery
By Stages
Stage 0
Stage I
Stage II
Stage III
Stage IV
By End User
Hospitals
Specialty Clinics
Home Healthcare
Others
By Country
GCC
Israel
Rest of Middle East
Africa
By Therapy
Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Surgery
By Stages
Stage 0
Stage I
Stage II
Stage III
Stage IV
By End User
Hospitals
Specialty Clinics
Home Healthcare
Others
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Bristol-Myers Squibb Company
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Novartis AG
Merck & Co., Inc.
Genentech Inc.
F. Hoffmann-La Roche AG.
Amgen Inc.
AstraZeneca
Daiichi Sankyo Company, Limited.
AB Sciences.
AgonOX, Inc.
Eisai Co., Ltd
GlaxoSmithKline, plc.
Pfizer, Inc.
Vical, Inc.
“*” marked represents similar segmentation in other categories in the respective section.